ABCG2- and ABCB1 Inhibition Using Supratherapeutic Doses of Erlotinib: Clinical Implications in the Treatment of Central Nervous System Metastases

Research output: Contribution to journalComment/Letter to the editorAcademic

Original languageEnglish
Pages (from-to)305
Number of pages1
JournalJournal of nuclear medicine : official publication, Society of Nuclear Medicine
Volume61
Issue number2
Early online date4 Oct 2019
DOIs
Publication statusPublished - 1 Feb 2020

Cite this